Experimental drug cuts Parkinson's-linked protein up to 60% in early trial

Experimental drug cuts Parkinson's-linked protein up to 60% in early trial

An experimental drug designed to silence a gene strongly linked to Parkinson's disease has shown encouraging effects in a first-in-human clinical trial, according to a study published in Nature Medicine. The drug, known as BIIB094, targets LRRK2, the most common genetic contributor to Parkinson's disease; variants in LRRK2 are known to increase the risk of developing the neurodegenerative disorder, which affects nearly 10 million people worldwid…